Showing 1001-1010 of 1604 results for "".
- HS Update: Studies Suggest TNF, IL-17, and JAK inhibitors May Play a Role in Treating HShttps://practicaldermatology.com/news/hs-update-studies-suggest-tnf-il-17-and-jak-inhibitors-may-play-a-role-in-treating-hs/2461627/Several new potential therapies for hidradenitis suppurativa (HS) are coming down the pike, according to research presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. Acelyrin, Inc.'s Izokibep led to HiSCR response at 12 weeks, including H
- Dermatologist Terrence A. Cronin Jr., MD, Named New AAD Presidenthttps://practicaldermatology.com/news/dermatologist-terrence-a-cronin-jr-md-named-new-aad-president/2461615/Terrence A. Cronin Jr., MD, FAAD, is the new President of the American Academy of Dermatology. He will start his one-year term at the close of the Academy's Annual Meeting. Dr. Cronin will also hold the same position for the American Academy of Dermatology Association, a sister
- Guselkumab Shows Greater Treatment Persistence than IL-17s in Both Bio-naïve and Bio-experienced Psoriasis Patientshttps://practicaldermatology.com/news/guselkumab-shows-greater-treatment-persistence-than-il-17s-in-both-bio-naive-and-bio-experienced-psoriasis-patients/2461613/Tremyfa (guselkumab) may beat out other biologics when it comes to patient persistence, and a post-hoc analysis of guselkumab showed improvements in scalp psoriasis and quality-of-life measures at week 48. Research found that bio-experienced and bio-naïve psoria
- LEO Pharma Adds to Global Leadership Teamhttps://practicaldermatology.com/news/leo-pharma-adds-to-global-leadership-team/2461607/Dr. Jacob Pontoppidan Thyssen is the new Executive Vice President and Chief Scientific Officer for LEO Pharma’s Research and Early Development arm. The company announced that a significant shift in R&D to a research model in early 2023. The change aims to drive the early-stage
- Bristol Myers Squibb Advances Melanoma Drug Candidate Opdivo in US and Europehttps://practicaldermatology.com/news/bristol-myers-squibb-advances-melanoma-drug-candidate-opdivo-in-us-and-europe/2461583/Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application (BLA) for Opdivo (nivolumab) as monotherapy in the adjuvant setting for the treatment of patients with completely resected stage IIB or IIC melanoma. The company also announced t
- Aldeyra Therapeutics Advances Investigational ADX 629 Into Phase 2 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/aldeyra-therapeutics-advances-investigational-adx-629-into-phase-2-trial-for-atopic-dermatitis/2461568/Aldeyra Therapeutics announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑629, an investigational oral RASP modulator, for the treatment of several systemic diseases, including atopic dermatitis. For the atopic dermatitis indication, the mul
- Cetaphil Launches Initiative to Raise Awareness of Connection Between Clothing and Sensitive Skinhttps://practicaldermatology.com/news/cetaphil-launches-initiative-to-raise-awareness-of-connection-between-clothing-and-sensitive-skin/2461567/Cetaphil announced it is launching a new initiative this month that aims to raise awareness of the connection between our clothes and skin. The initiative includes a partnership with Hillary Taymour, designer and founder of fashion house Collina Strada, and board-certified dermatologist
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- ASA Renews Support of SPOTS Programhttps://practicaldermatology.com/news/asa-renews-support-of-spots-program/2461565/The American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a community outreach program designed to teach students from preschool through high school about the importance of early detectio
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu